ONC.TO Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 23:00):

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer...

Stats
Dzisiejszy wolumen	33 155.00
Średni wolumen	83 432.00
Kapitalizacja rynkowa	120.67M
EPS	$0 ( 2024-03-06 )
Następna data zysków	( $-0.110 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.90
ATR14	$0.00300 (0.19%)

Oncolytics Biotech Inc Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Oncolytics Biotech Inc Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$-403 000 (0.00 %)
EPS:	$-0.410

FY	2023
Przychody:	$0
Zysk brutto:	$-403 000 (0.00 %)
EPS:	$-0.410

FY	2022
Przychody:	$0
Zysk brutto:	$-392 000 (0.00 %)
EPS:	$-0.430

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.490

Financial Reports:

No articles found.

Oncolytics Biotech Inc

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Aktualne aktualizacje dla Oncolytics Biotech Inc [ONC.TO]

Upcoming Earnings Alert